| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,010 |
2,828 |
$224K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,793 |
1,754 |
$181K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,118 |
1,110 |
$91K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,023 |
1,012 |
$51K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
478 |
477 |
$51K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
935 |
845 |
$40K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
615 |
533 |
$26K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
406 |
387 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,384 |
2,273 |
$10K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
67 |
65 |
$9K |
| S9083 |
Global fee urgent care centers |
82 |
75 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
98 |
96 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
295 |
157 |
$4K |
| 99051 |
|
569 |
535 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
31 |
30 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
35 |
30 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
31 |
30 |
$772.78 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
31 |
30 |
$761.44 |